### **Overview** Dishman Carbogen Amcis Ltd (DCAL) is a global Contract Development and Manufacturing Organization (CDMO) headquartered in Ahmedabad, India. The company operates as an integrated outsourcing partner for the pharmaceutical and biopharmaceutical industries, offering end-to-end services from process research to commercial manufacturing of Active Pharmaceutical Ingredients (APIs), intermediates, and finished drug products. With a presence in six countries—India, Switzerland, France, China, the UK, and the Netherlands—DCAL combines geographic diversity with technical excellence to serve innovator clients worldwide. The company’s operations are anchored by its Swiss subsidiary, **CARBOGEN AMCIS AG**, a wholly owned entity that drives innovation and high-value development projects across the clinical lifecycle. As of November 2025, DCAL operates **10 manufacturing sites** and **28 R&D labs** globally, all compliant with cGMP standards and approved by major regulatory agencies including the US FDA, EDQM, Swissmedic, and PMDA. --- ### **Strategic Focus & Investment** - **Capital Investment:** The company has committed over **₹10,000 million (INR 1,000 crores)** in large-scale, multi-purpose manufacturing infrastructure, underscoring its long-term growth strategy. - **ADC Leadership:** DCAL is expanding its **Antibody-Drug Conjugate (ADC)** manufacturing footprint across key sites in **Neuland and Aarau (Switzerland), Manchester (UK), and Shanghai (China)**. A single ADC molecule is now being produced across multiple global facilities, demonstrating seamless integration and visibility into **three years of forward orders**. - **Modular Service Model:** While DCAL does not manufacture antibodies (requiring high capital and specialized expertise), it offers customers **flexible engagement models**—full-service integration or modular services (e.g., linker synthesis, payload manufacturing, conjugation). - **Peptide Conjugation:** In addition to ADCs, the company is exploring **peptide-drug conjugation**, diversifying its bioconjugation capabilities. --- ### **Global Manufacturing & Operational Highlights** #### **India – Bavla & Naroda Facilities** - The **Bavla** site houses **Asia’s largest Highly Potent (HiPo) API facility**, capable of multi-ton production—significantly exceeding the Swiss site’s 1.6–2-ton limit. - The **Bavla HiPo facility (OEB 4+)** supports end-to-end development and commercial manufacturing of oncology APIs, with **EDQM and US FDA approvals secured in 2024**. - **Naroda Unit I & II** feature large-scale reactors (up to 10 KL), advanced drying systems (ANFDs), RLAF-controlled sampling areas, and NIR-based QC for rapid solvent release. - Combined, the Indian operations have the potential to generate up to **INR 1,000 crores in revenue**. - The Indian units are now fully operational post-regulatory resolution, having addressed EDQM observations through facility rebuilds and a new German-sourced QC lab. #### **Switzerland – Bubendorf, Neuland, Vionnaz, Hunzenschwil, Aarau** - **Bubendorf**: Focuses on **late-phase and commercial APIs**, including highly potent oncology compounds. A **CHF 25+ million co-investment** with a Japanese client is expanding ADC capacity. - **Vionnaz**: Specializes in **Highly Potent APIs up to Category 5**, including warheads and linkers. Site has passed multiple Swissmedic audits and supports GMP manufacturing at small scale. - **Neuland (India)**: Despite the name, is a Swiss-located facility focused on **early-phase API development** and rapid cGMP kilo-lab supply. - **Aarau & Hunzenschwil**: Support **process research** and **scale-up**, with Hunzenschwil’s new facility scheduled to launch in 2025. - Swiss operations hold **over CHF 200 million in commercial and development purchase orders**, driving robust revenue visibility. #### **France – Saint-Beauzire Facility** - A **new greenfield parenteral manufacturing site**, operational since 2023, specializes in **sterile injectables** (liquid and lyophilized) with **aseptic filling capacity up to 400 liters**. - Equipped to handle **OEB 4+ compounds**, the facility has two automated lines, integrated R&D, and QC labs. It passed ANSM audit and received GMP certification. - Revenue from France was **€1.2 million in Q1 FY25**, with **€18 million expected for EBITDA breakeven** and potential revenue of **€45 million at 35% operating margin**. - Expected to grow to **$40–45 million annually over 3–5 years**, with **€9.5 million committed revenue** in FY24–25. #### **Other International Sites** - **Shanghai (China)**: Achieved **local GMP certification**, enabling direct supply to Chinese API customers. Recent profitability improved to **>25% EBITDA margin**. - **Manchester (UK)**: Focuses on **non-GMP custom synthesis and intermediate production** (up to 4,500L). 60% of output supports R&D; 25% is commercial. - **Veenendaal (Netherlands)**: Integrated site for **complex APIs and vitamin D analogues**, sourcing cholesterol from wool grease. --- ### **Financial & Business Performance** - **Revenue Streams:** - **100% of turnover** comes from **CDMO/CRAMS services**, emphasizing a focused business model. - **Development vs. Commercial Revenue**: Historically split **~50:50**, with **late-phase and validation projects** generating the highest margins. - Recent quarters driven by **Swiss commercial supply**, with upcoming periods expected to be development-led. - **Q1 FY25 Revenue:** ₹5,237.8 million (↓27.6% YoY), primarily due to **timing delays of CHF 9.8 million** in commercial and development projects. - **Segment Performance:** - **DCAL India NCE APIs & Intermediates**: Grew 114.5% YoY (₹822.3 million). - **CARBOGEN AMCIS CRAMS**: ₹3,392.3 million (↓39.6% YoY). - **Cholesterol & Vitamin D Analogues**: ₹778.8 million (↓16.4%), impacted by raw material cost pressures. - **Margins:** Late-phase projects yield highest profitability. Indian CRAMS expected to return to **~40% EBITDA margins** (from ~11%). - **Exports:** Constitute **89.94% of FY22–23 turnover**, with key markets in the **USA, UK, EU, Japan, and Brazil**. --- ### **Innovation & Technology** - **Digital Transformation:** - Group-wide **SAP S/4HANA rollout** underway to harmonize operations. - Initiatives include **cloud ERP migration, plant Wi-Fi, WMS, SAP PM**, and analytical instrument upgrades. - **Green Chemistry:** - Implemented **enzyme-catalyzed, water-based reactions** to enhance sustainability. - Upgraded **ultrafiltration and filter dryers** at commercial plants. - **Research & Development:** - R&D pipeline at **all-time high**, with **~16–17 molecules in Phase III** and **three in validation**. - Focus on **vitamin D analogues (e.g., calcifediol)**, with clinical advantages over D3 under patent review. - Strong client collaboration, including **co-investment agreements with Japanese, US, and EU biotech firms**. - **Automation & AI:** Strategic focus on **digital transformation**, **AI integration**, and **continuous flow chemistry** to drive efficiency and innovation. --- ### **Sustainability & Compliance** - All sites comply with global **cGMP, environmental, and safety standards**. - In-house technology development: **No external tech imports in last 3 years**. - **Waste and energy efficiency** improved via process optimization, effluent reduction, and solvent recovery. - **Quality Management System (QMS)** overhaul across global entities for consistent standards. --- ### **Challenges & Mitigation** - **Regulatory Delays:** Bavla site faced EDQM audit issues (now resolved); French greenfield start-up delayed (now operational). - **Raw Material Costs:** Dutch cholesterol/Vitamin D segment impacted by **wool grease price volatility**—supplier contracts being renegotiated. - **Regional Demand Variability:** - U.S. and Japanese markets strong. - European demand soft due to customer-side disruptions. - Quats and agrochemicals sector slowdown in India—expected to recover in FY26.